{"prompt": "['- Local injection site reactions (ISRs) with signs and symptoms such as erythema,', 'induration, swelling, pain, hypoaesthesia and discomfort', 'Hypersensitivity reactions / anaphylaxis are systemic reactions caused activation of mast', 'cells and basophils by antigen-bound IgE that results in degranulation and release of', 'inflammatory mediators. Hypersensitivity reactions / anaphylaxis events are likely to start', 'mildly and increase in number and severity over time. Severe hypersensitivity, including', 'anaphylaxis, has been observed in clinical trials with treatment of Perjeta IV. Patients in this', 'study who experience a Grade 4 allergic reaction or acute respiratory distress syndrome', '(ARDS) should be discontinued from study treatment. Since there is a potential for delayed', 'onset, patients should be instructed to contact the treating physician with any concerns,', 'signs or symptoms subsequent to treatment administration. Administration-related reactions', 'may be difficult to distinguish from hypersensitivity reactions.', 'In this study, if a loading dose of Perjeta IV is required, it will be given over 60 ( 10)', 'minutes, followed by an observation period of 60 minutes. If the loading dose infusion is well', 'tolerated, subsequent infusions may be administered over a period of 30 minutes ( 10) with', 'an observation period of 30 minutes. If symptoms occur, the infusion should be slowed down', 'or interrupted and appropriate medical therapies should be administered. The observation', 'period should be completed prior to the subsequent Herceptin IV infusion. Premedication', 'with antipyretics, antihistamines, or corticosteroids may be administered before Perjeta IV', 'administration.', 'For pertuzumab and trastuzumab FDC SC administration, patients should be monitored for', '30 minutes after their first dose regardless of whether a loading dose is required. Patients', 'should be monitored for 10 - 15 minutes following subsequent administrations unless a', 'loading dose is required. If a patient requires a loading dose after their first pertuzumab and', 'trastuzumab FDC SC treatment, they should be monitored for 30 minutes after dosing. If', 'ARRs occur, patients must be monitored until complete resolution of signs and symptoms.', 'Perjeta IV and pertuzumab and trastuzumab FDC SC will be administered by staff who have', 'immediate access to emergency equipment and are trained to monitor for, and respond to,', 'medical emergencies.', \"Please refer to the Perjeta Investigator's Brochure for the most recent data related to the risk\", 'of hypersensitivity reactions.', '5.1.1.2', 'Symptomatic Left Ventricular Systolic Dysfunction', \"Similar to trastuzumab, pertuzumab's interaction with HER2 may be associated with a risk of\", 'symptomatic LVSD. Cardiac dysfunction may manifest as an asymptomatic or mildly', 'symptomatic decrease in LVEF (NCI CTCAE, Grade 1 and Grade 2) or as a symptomatic', 'decreased in LVEF / CHF (NCI CTCAE, Grade 3; NYHA Class III or IV). Please refer to', 'Appendix 6 for management of patients with decreased LVEF.', 'In the Roche pivotal trial WO20698/TOC4129g (CLEOPATRA) in MBC patients, treatment', 'with P+H IV and docetaxel was not associated with increases in the incidence of', 'symptomatic LVSD or LVEF declines compared with placebo in combination with Herceptin', 'IV and docetaxel. The incidence of symptomatic LVSD was 1.5% (6/408) for patients', 'receiving P+H IV and docetaxel (events in the treatment period only) and 1.5% (7/396) in the', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '57 / Protocol MO40628, Version 12']['placebo arm. Regardless of treatment arm, patients who had received prior anthracyclines or', 'prior radiotherapy to the chest area were at higher risk of decreased LVEF. In the Roche', 'Phase Il WO209697 study (NEOSPHERE) of neoadjuvant P+H IV and docetaxel, the', 'incidence of left ventricular dysfunction defined as LVEF decline 10% to below 50% was', 'higher in the Perjeta IV plus docetaxel-treated groups (7.4% with Perjeta IV plus docetaxel,', '8.4% P+H IV plus docetaxel) than the Herceptin IV plus docetaxel treated group (1.9%). An', 'increased incidence of LVEF declines was observed in patients treated in the Perjeta IV plus', 'Herceptin IV and docetaxel. Left ventricular ejection fraction recovered to 50% in all', 'patients. In the ongoing Roche Phase Il WO29217 study (BERENICE; neoadjuvant', 'anthracycline / taxane based regimens given in combination with P+H IV), the overall', 'incidence of LVEF declines and symptomatic LVD in the neoadjuvant period is consistent', 'with previous data in the neoadjuvant setting.', 'Perjeta has not been studied in patients with the following: a pre-treatment LVEF value of', '< 50%; a prior history of CHF; decreases in LVEF to < 50% during prior Herceptin adjuvant', 'therapy; conditions that could impair left ventricular function such as uncontrolled', 'hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment, or', 'a cumulative prior anthracycline exposure to > 360 mg/m\u00b2 of doxorubicin or its equivalent.', 'Subjects with significant cardiac disease or baseline LVEF < 55% are not eligible for this', 'study. As in all Perjeta trials, study patients must undergo routine cardiac monitoring by', 'ECHO or MUGA scan. During the screening / baseline period, complete medical history', 'information will be collected from all patients to explore possible risk factors for treatment-', 'associated CHF. Monitoring of LVEF is required while patients are receiving study treatment', 'and up to 24 months following discontinuation of study treatment (see Appendix 1). If', 'symptomatic LVSD (heart failure; SAE of NCI CTCAE v4.0 Grade 3 or 4; NYHA Class III or', 'IV) develops, the patient must be monitored carefully with repeat LVEF assessments.', 'Symptomatic LVSD should be treated and followed according to standard medical practice.', 'Refer to the algorithm in Appendix 6 for decisions regarding the continuation or', 'discontinuation of study treatment based on LVEF assessment in asymptomatic patients.', \"Please refer to the Perjeta Investigator's Brochure for the most recent data relating to risk of\", 'LVSD and CHF.', '5.1.1.3', 'Epidermal Growth Factor Receptor (HER1)-Related Toxicities', 'Pertuzumab inhibits HER2 heterodimerization with other members of the HER family', 'including HER1/EGFR. As a result, pertuzumab may cause toxicities associated with the use', 'of EGFR tyrosine kinase inhibitors such as diarrhoea, rash and other dermatologic toxicities', '(e.g., dry skin, pruritus, nail disorders, mucositis).', 'The most recent data relating to the risk of EGFR-related toxicities are found in the Perjeta', \"Investigator's Brochure.\", '5.1.1.3.1', 'Diarrhoea', 'Diarrhoea has been observed in approximately 60% of patients (treatment-related diarrhoea', 'in 50% of patients) being treated with Perjeta IV in Phase Il single-agent studies, and in up', 'to 90% of patients in combination therapy studies. Diarrhoea was NCI CTCAE Grade 1 or 2', 'in the majority of cases. To prevent dehydration, early treatment of diarrhoea with anti-', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '58 / Protocol MO40628, Version 12']\n\n###\n\n", "completion": "END"}